calcium chloride + icodextrin + magnesium chloride + sodium chloride + sodium lactate: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
calcium chloride + icodextrin + magnesium chloride + sodium chloride + sodium lactate: clinical details
Prescribing considerations
- Use only within a physician-supervised CAPD or APD prescription for chronic renal failure; it is not recommended for acute renal failure or children.
- Review abdominal and respiratory conditions that may make peritoneal dialysis unsafe or ineffective.
- Assess lactic-acidosis risk, nutritional status, potassium deficiency, hydration and potential loss of dialysable medicines, proteins and water-soluble vitamins.
- Ensure diabetes and hospital records prominently specify that only a verified glucose-specific testing system is suitable.
- Investigate cloudy effluent promptly; retain the drained bag and batch number and obtain appropriate microbiological samples.
Contraindications and cautions
- Hypersensitivity to an ingredient or allergy to icodextrin or starch-based polymers such as maize starch
- Maltose or isomaltose intolerance
- Glycogen storage disease
- Pre-existing severe lactic acidosis
- Uncorrectable mechanical defects that prevent effective peritoneal dialysis or increase infection risk
- Documented loss of peritoneal function or extensive adhesions compromising peritoneal function
Monitoring
- Fluid balance, body weight and signs of overhydration or dehydration
- Haematology, blood chemistry and electrolytes, including sodium, chloride, magnesium and bicarbonate
- Potassium, particularly with cardiac glycosides
- Glycaemic control and glucose-monitoring technology
- Peritoneal effluent, catheter site and signs of peritonitis or aseptic peritoneal reaction
- Lactic acidosis in patients with relevant disease states or interacting medicines
- Serum amylase and liver-associated enzymes where clinically relevant
Clinical pharmacology
Icodextrin is a starch-derived colloid osmotic agent supporting sustained intraperitoneal ultrafiltration. Amylase hydrolyses it into smaller glucose polymers, including maltose, which can interfere with some glucose assays.
Formulation and product differences
- Sterile, clear, colourless electrolyte solution for intraperitoneal use only.
- Available in flexible PVC single-bag and twin-bag presentations with luer or spike connectors; not all authorised presentations may be marketed.
- Contains sodium, calcium, magnesium, chloride and lactate but no added potassium.
- Check compatibility before adding another medicine. Aminoglycosides must not be mixed with penicillins because of chemical incompatibility.
calcium chloride + icodextrin + magnesium chloride + sodium chloride + sodium lactate interactions
Formal interaction studies have not been performed. Important practical interactions arise from dialysis, maltose formation and the lactate-containing formulation.
Non-glucose-specific blood glucose meters and test strips
GDH-PQQ, GDO and some GDH-FAD systems may report falsely high glucose, risking excessive insulin or missed hypoglycaemia.
Insulin
Changing from glucose-based dialysis fluid can alter insulin requirements, requiring specialist review of glucose control and insulin therapy.
Dialysable medicines
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.